Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
Veronica Agostinelli,1 Lucia Musacchio,2 Floriana Camarda,2 Vanda Salutari,2 Maria Vittoria Carbone,2 Viola Ghizzoni,2 Camilla Nero,2 Caterina Ricci,2 Maria Teresa Perri,2 Elena Giudice,3 Sara Lardino,3 Rossana Berardi,1 Giovanni Scambia,2,3 Domenica Lorusso2,3 1Oncologic Clinic, Università Politecn...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-09-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/therapeutic-potential-of-tisotumab-vedotin-in-the-treatment-of-recurre-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1797671505806491648 |
|---|---|
| author | Agostinelli V Musacchio L Camarda F Salutari V Carbone MV Ghizzoni V Nero C Ricci C Perri MT Giudice E Lardino S Berardi R Scambia G Lorusso D |
| author_facet | Agostinelli V Musacchio L Camarda F Salutari V Carbone MV Ghizzoni V Nero C Ricci C Perri MT Giudice E Lardino S Berardi R Scambia G Lorusso D |
| author_sort | Agostinelli V |
| collection | DOAJ |
| description | Veronica Agostinelli,1 Lucia Musacchio,2 Floriana Camarda,2 Vanda Salutari,2 Maria Vittoria Carbone,2 Viola Ghizzoni,2 Camilla Nero,2 Caterina Ricci,2 Maria Teresa Perri,2 Elena Giudice,3 Sara Lardino,3 Rossana Berardi,1 Giovanni Scambia,2,3 Domenica Lorusso2,3 1Oncologic Clinic, Università Politecnica delle Marche, Ancona, Italy; 2Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 3Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Vanda Salutari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, Roma, 00168, Italy, Tel +39-06-3015-3234, Email vanda.salutari@policlinicogemelli.itAbstract: Cervical cancer is the fourth most common type of cancer in women worldwide. It is associated with a high death rate, despite the fact that it is a nearly 100% preventable disease because of very effective primary and secondary preventive strategies. Advanced and recurrent disease is uncurable with a high relapse risk and the second-line therapies are limited with modest response rates and short durability. Investigating alternative mechanisms of action is crucial because of the high request for effective new therapies. Tisotumab vedotin (TV) is the first antibody-drug conjugated to target a cell surface-expressed tissue factor, and preliminary data in patients with metastatic and recurrent cervical cancer have been promising. In addition, the trials showed a favorable tolerability profile, with limited incidence of grade 3 or worse adverse events. According to the data of ENGOT-cx6/GOG-3023/innovaTV 204, the US Food and Drug Administration granted expedited approval of TV on September 20, 2021, for women with recurrent or metastatic cervical cancer. Actually, two other trials testing TV alone or in combination with other agents are ongoing. ENGOT-cx8/GOG-3024/innovaTV 205 is a Phase Ib/II trial of TV in combination with platinum or bevacizumab or pembrolizumab, in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy or who have progressed after no more than two prior systemic therapies. ENGOT-cx12/GOG-3057/InnovaTV 301 is a Phase 3 trial of TV vs investigator’s choice chemotherapy in patients with advanced or recurrent cervical cancer who had received no more than 2 prior chemotherapy lines. The outcomes of these two trials will potentially confirm and reinforce the use of TV as a new standard of care in advanced or recurrent cervical cancer.Keywords: cervical cancer, gynecological cancer, antibody–drug conjugate, tissue factor |
| first_indexed | 2024-03-11T21:16:31Z |
| format | Article |
| id | doaj.art-0415cde31d46464c80fc4f09a64eed29 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-03-11T21:16:31Z |
| publishDate | 2023-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-0415cde31d46464c80fc4f09a64eed292023-09-28T18:12:51ZengDove Medical PressCancer Management and Research1179-13222023-09-01Volume 151063107286982Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging DataAgostinelli VMusacchio LCamarda FSalutari VCarbone MVGhizzoni VNero CRicci CPerri MTGiudice ELardino SBerardi RScambia GLorusso DVeronica Agostinelli,1 Lucia Musacchio,2 Floriana Camarda,2 Vanda Salutari,2 Maria Vittoria Carbone,2 Viola Ghizzoni,2 Camilla Nero,2 Caterina Ricci,2 Maria Teresa Perri,2 Elena Giudice,3 Sara Lardino,3 Rossana Berardi,1 Giovanni Scambia,2,3 Domenica Lorusso2,3 1Oncologic Clinic, Università Politecnica delle Marche, Ancona, Italy; 2Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 3Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, ItalyCorrespondence: Vanda Salutari, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, Roma, 00168, Italy, Tel +39-06-3015-3234, Email vanda.salutari@policlinicogemelli.itAbstract: Cervical cancer is the fourth most common type of cancer in women worldwide. It is associated with a high death rate, despite the fact that it is a nearly 100% preventable disease because of very effective primary and secondary preventive strategies. Advanced and recurrent disease is uncurable with a high relapse risk and the second-line therapies are limited with modest response rates and short durability. Investigating alternative mechanisms of action is crucial because of the high request for effective new therapies. Tisotumab vedotin (TV) is the first antibody-drug conjugated to target a cell surface-expressed tissue factor, and preliminary data in patients with metastatic and recurrent cervical cancer have been promising. In addition, the trials showed a favorable tolerability profile, with limited incidence of grade 3 or worse adverse events. According to the data of ENGOT-cx6/GOG-3023/innovaTV 204, the US Food and Drug Administration granted expedited approval of TV on September 20, 2021, for women with recurrent or metastatic cervical cancer. Actually, two other trials testing TV alone or in combination with other agents are ongoing. ENGOT-cx8/GOG-3024/innovaTV 205 is a Phase Ib/II trial of TV in combination with platinum or bevacizumab or pembrolizumab, in patients with recurrent or metastatic cervical cancer who have not received prior systemic therapy or who have progressed after no more than two prior systemic therapies. ENGOT-cx12/GOG-3057/InnovaTV 301 is a Phase 3 trial of TV vs investigator’s choice chemotherapy in patients with advanced or recurrent cervical cancer who had received no more than 2 prior chemotherapy lines. The outcomes of these two trials will potentially confirm and reinforce the use of TV as a new standard of care in advanced or recurrent cervical cancer.Keywords: cervical cancer, gynecological cancer, antibody–drug conjugate, tissue factorhttps://www.dovepress.com/therapeutic-potential-of-tisotumab-vedotin-in-the-treatment-of-recurre-peer-reviewed-fulltext-article-CMARcervical cancergynecological cancerantibody–drug conjugatetissue factor. |
| spellingShingle | Agostinelli V Musacchio L Camarda F Salutari V Carbone MV Ghizzoni V Nero C Ricci C Perri MT Giudice E Lardino S Berardi R Scambia G Lorusso D Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data Cancer Management and Research cervical cancer gynecological cancer antibody–drug conjugate tissue factor. |
| title | Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data |
| title_full | Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data |
| title_fullStr | Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data |
| title_full_unstemmed | Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data |
| title_short | Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data |
| title_sort | therapeutic potential of tisotumab vedotin in the treatment of recurrent or metastatic cervical cancer a short report on the emerging data |
| topic | cervical cancer gynecological cancer antibody–drug conjugate tissue factor. |
| url | https://www.dovepress.com/therapeutic-potential-of-tisotumab-vedotin-in-the-treatment-of-recurre-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT agostinelliv therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT musacchiol therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT camardaf therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT salutariv therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT carbonemv therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT ghizzoniv therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT neroc therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT riccic therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT perrimt therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT giudicee therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT lardinos therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT berardir therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT scambiag therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata AT lorussod therapeuticpotentialoftisotumabvedotininthetreatmentofrecurrentormetastaticcervicalcancerashortreportontheemergingdata |